Product Name:(R)-glycidol

IUPAC Name:[(2R)-oxiran-2-yl]methanol

CAS:57044-25-4
Molecular Formula:C3H6O2
Purity:97%
Catalog Number:CM115979
Molecular Weight:74.08

Packing Unit Available Stock Price($) Quantity
CM115979-100g in stock ƐŪƚ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:57044-25-4
Molecular Formula:C3H6O2
Melting Point:-
Smiles Code:OC[C@@H]1CO1
Density:
Catalog Number:CM115979
Molecular Weight:74.08
Boiling Point:
MDL No:MFCD00074873
Storage:

Column Infos

Alicyclic Heterocycles
When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.
Seladelpar
Recently, CymaBay Therapeutics announced it has submitted a New Drug Application (NDA) to the FDA for investigational treatment, seladelpar, for the management of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to ursodeoxycholic acid (UDCA). CymaBay has requested a Priority Review of the NDA that, if accepted, would mean the FDA would plan to complete its review within six months of accepting the application. Seladelpar has been granted Breakthrough Therapy Designation by the FDA and is the only potent, selective, orally active delpar, or PPARδ agonist, with Phase 3 trial results demonstrating a statistically significant improvement in markers of cholestasis related to risk of progression and PBC-related pruritus.